- Home
- SNGX vs XBIO Comparison
SNGX vs XBIO Comparison
Compare SNGX & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- XBIO
- Stock Information
- Founded
- SNGX 1987
- XBIO N/A
- Country
- SNGX United States
- XBIO United States
- Employees
- SNGX N/A
- XBIO N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- SNGX Health Care
- XBIO Health Care
- Exchange
- SNGX Nasdaq
- XBIO Nasdaq
- Market Cap
- SNGX 7.4M
- XBIO 6.3M
- IPO Year
- SNGX 1987
- XBIO N/A
- Fundamental
- Price
- SNGX $2.43
- XBIO $4.03
- Analyst Decision
- SNGX
- XBIO Hold
- Analyst Count
- SNGX 0
- XBIO 1
- Target Price
- SNGX N/A
- XBIO N/A
- AVG Volume (30 Days)
- SNGX 31.1K
- XBIO 4.8K
- Earning Date
- SNGX 03-14-2025
- XBIO 03-20-2025
- Dividend Yield
- SNGX N/A
- XBIO N/A
- EPS Growth
- SNGX N/A
- XBIO N/A
- EPS
- SNGX N/A
- XBIO N/A
- Revenue
- SNGX $364,183.00
- XBIO $2,523,427.00
- Revenue This Year
- SNGX N/A
- XBIO N/A
- Revenue Next Year
- SNGX $76.64
- XBIO N/A
- P/E Ratio
- SNGX N/A
- XBIO N/A
- Revenue Growth
- SNGX N/A
- XBIO 7.15
- 52 Week Low
- SNGX $1.83
- XBIO $2.78
- 52 Week High
- SNGX $14.88
- XBIO $5.20
- Technical
- Relative Strength Index (RSI)
- SNGX 46.06
- XBIO 45.61
- Support Level
- SNGX $2.35
- XBIO $3.91
- Resistance Level
- SNGX $2.47
- XBIO $4.24
- Average True Range (ATR)
- SNGX 0.13
- XBIO 0.17
- MACD
- SNGX 0.04
- XBIO -0.01
- Stochastic Oscillator
- SNGX 61.36
- XBIO 28.93
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.